Fredag 21 Augusti | 19:42:42 Europe / Stockholm
Est. tid*
2026-10-29 08:00 Kvartalsrapport 2026-Q3
2026-08-17 - Extra Bolagsstämma 2026
2026-07-10 - Kvartalsrapport 2026-Q2
2026-04-30 - Kvartalsrapport 2026-Q1
2026-04-29 - X-dag ordinarie utdelning AKBM 0.00 NOK
2026-04-28 - Årsstämma
2026-02-12 - Bokslutskommuniké 2025
2025-10-31 - Kvartalsrapport 2025-Q3
2025-07-11 - Kvartalsrapport 2025-Q2
2025-04-30 - Kvartalsrapport 2025-Q1
2025-04-28 - X-dag ordinarie utdelning AKBM 0.00 NOK
2025-04-25 - Årsstämma
2025-02-12 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-09-09 - X-dag ordinarie utdelning AKBM 45.00 NOK
2024-09-03 - Extra Bolagsstämma 2024
2024-07-12 - Kvartalsrapport 2024-Q2
2024-04-26 - Kvartalsrapport 2024-Q1
2024-04-17 - X-dag ordinarie utdelning AKBM 0.00 NOK
2024-04-16 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-11-01 - Kvartalsrapport 2023-Q3
2023-07-14 - Kvartalsrapport 2023-Q2
2023-04-28 - Kvartalsrapport 2023-Q1
2023-04-21 - X-dag ordinarie utdelning AKBM 0.00 NOK
2023-04-20 - Årsstämma
2023-02-15 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-04-29 - Kvartalsrapport 2022-Q1
2022-04-21 - X-dag ordinarie utdelning AKBM 0.00 NOK
2022-04-20 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-07-14 - Kvartalsrapport 2021-Q2
2021-04-29 - Kvartalsrapport 2021-Q1
2021-03-15 - X-dag ordinarie utdelning AKBM 0.00 NOK
2021-03-12 - Årsstämma
2021-02-16 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-07-15 - Kvartalsrapport 2020-Q2
LandNorge
ListaOslo Bors
SektorHandel & varor
IndustriDagligvaror
Aker BioMarine är verksamt inom bioteknik. Bolaget är specialiserat inom utveckling av kostillskott. Produktportföljen är bred och inkluderar exempelvis omega-3 olja, näringstillskott för djur, samt proteintillskott för fiskeodling. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Kunderna består av både privata aktörer samt grossister. Aker BioMarine grundades år 2006 och har sitt huvudkontor i Oslo.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Aker BioMarine ASA: Extraordinary general meeting held - merger plan approved and condition for completion of cash offer fulfilled

2026-08-17 09:52:06
Oslo, 17 August 2026: Reference is made to the stock exchange announcement
published by Aker BioMarine ASA (the "Company") on 16 July 2026 regarding the
announcement of a triangular merger pursuant to Chapter 13 of the Norwegian
Public Limited Liability Companies Act between Aker BioMarine ASA and Aker
Capital NewCo AS ("ACN"), with ACN as the surviving legal entity (the "Merger"),
together with a related cash offer from Aker Capital AS to the shareholders of
the Company (the "Cash Offer"). Notice of an extraordinary general meeting to
approve the merger plan for the Merger was published on 17 July 2026.

The Company has today held the extraordinary general meeting. All items on the
agenda were resolved in accordance with the proposals from the Board of
Directors, including approval of the merger plan for the Merger. The minutes
from the extraordinary general meeting are attached hereto and are also
available on the Company's website www.akerbiomarine.com/AGM. The decision to
approve the Merger will be filed with the Norwegian Register of Business
Enterprises. Completion of the merger remains conditional upon customary closing
conditions as described in the merger plan.

Completion of the Cash Offer was conditional upon approval of the Merger by the
extraordinary general meeting in the Company. Settlement of the Cash Offer will
take place no later than three trading days after todays approval of the Merger
by the extraordinary general meeting in the Company.

For further information, please contact
Lars Jacobsen, General Counsel
Mobile: +47 906 05 306
Email: lars.jacobsen@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.
he Norwegian Securities Trading Act.\